Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
But PFS data are lacking, and there are questions about first and second-line plans.
Three private biotechs enter clinical trials, one targeting KRAS.
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
$650m buys the group rights to RemeGen’s RC148.
The company secures funding to push its lead candidate towards US approval.
